NCT00348387已完成3 期
Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 600
- 试验地点
- 2
- 主要终点
- To provide information concerning the immunogenicity of IMOVAX Polio™ vaccine
研究概览
简要总结
This study is intended to support the registration of IMOVAX Polio in China.
The primary objective of this Pase III trial is to compare IMOVAX Polio to the current Chinese standard of care (OPV) that is administered following a schedule of 2-3-4 months. The objective is to demonstrate that after the 3 doses primary series, in terms of seroprotection rates, IMOVAX Polio is not inferior to OPV. The safety of IPV will be assessed after each IPV dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 60 Days 至 70 Days（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 2 months (60-70 days) on the day of inclusion into the study
- •Born at full term pregnancy ( over 36 weeks) with a birth weight ≥ 2.5 kg 2Ibs) or more
- •Parent(s) or legal representative able to understand and give authorization and sign informed consent for participation
- •Able to attend all planned clinic appointment and obey and follow all study instructions
排除标准
- •Taking part in another clinical trial during the 4 weeks before the first trial vaccination
- •Have plans to take part in another clinical trial d during this trial period
- •Inborn or acquired decreased body natural defense, undertaking treatment that can reduce body's natural defense such as cancer drugs, radiation in the past six months or long term corticosteroid treatment
- •Systemic reaction to any vaccine component or history of life-threatening reaction to study vaccine or any vaccine with the same ingredient(s)
- •Prolonged or long time illness that could interfere with study or full participation
- •Received blood or blood-derived products since birth
- •Received any vaccine in the 4 weeks before the first trial vaccination is given (except BCG and hepatitis B)
- •Have plans to receive any vaccine in the 4 weeks after the (or any) study vaccination is given (except DTacP)
- •Previous vaccination against the poliomyelitis infection with the trial vaccine or another vaccine
- •History of poliomyelitis infection (confirmed either by symptoms, blood or other laboratory test)
- •Clinical or serological evidence of systemic illness including hepatitis B, hepatitis C or Human immunodeficiency virus (HIV)
- •Bleeding disorder or a low platelet which do not allow vaccination into the muscle
- •Had seizures in the past
- •Febrile illness (axillary temperature ≥ 37.1°C) or acute illness on the day of inclusion
结局指标
主要结局
To provide information concerning the immunogenicity of IMOVAX Polio™ vaccine
时间窗: 1 month post-vaccination 3
次要结局
- To provide information concerning the safety of IMOVAX Polio™ vaccine(Entire study period)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
4 期
A Study of the Safety of IMOVAX Polio™ in ChinaPoliomyelitisPolioNCT01244464Sanofi800
已完成
4 期
A Safety Study of IMOVAX Polio Vaccine in Selected Cities in ChinaPolioPoliomyelitisNCT01278433Sanofi Pasteur, a Sanofi Company5,007
已完成
4 期
Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in JapanPoliomyelitisPolioNCT02005536Sanofi Pasteur, a Sanofi Company60
已完成
4 期
Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis VaccinePolioPoliomyelitisNCT01475539Sanofi Pasteur, a Sanofi Company456
进行中（未招募）
不适用
A Safety Study of IMOVAX Polio Vaccine in Selected Cities in ChinaPoliomyelitisEUCTR2015-005186-23-Outside-EU/EEASanofi Pasteur China5,007